Carboplatin AUC10 in metastatic Seminoma
(Topic: “Real world evidence (except case studies)”)
R. Eldebri 1, J. Shamash 1
(1) Barts Health NHS Trust – United Kingdom
This study presents a multicentric retrospective analysis aimed at evaluating the use of carboplatin AUC10 for treating advanced seminoma. The objectives were to assess adherence to clinical guidelines, patient outcomes, and any adverse effects. Data were collected from five cancer centers, including Addenbrookes, Barts, Colchester, Ipswich, and Guys Cancer Centre, involving 84 patients treated from January 2021 to December 2023.
Patients had a median age of 42.3 years, with 75% presenting with de novo metastatic seminoma, and 25% had relapsed disease. The majority (94.4%) completed three cycles of carboplatin, with 5.5% requiring four cycles. Approximately 22.6% of patients needed dose reductions due to haematological toxicity. Adverse events included 7.14% of patients developing neutropenic sepsis, and 15.6% requiring platelet transfusions.
Overall, the study reports favorable outcomes, with a 96.3% relapse-free rate and 100% marker normalization. The three-year progression-free survival was 75%, with a relapse rate of 3.6%. Despite some toxicities, the regimen showed efficacy and tolerability, comparable to previously published data on seminoma treatment.
ABSTRACT CODE: IUC20769-89